The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
Latest news and blogs
News |
UK life sciences plan falls short, says ABPI
News |
Equitable access to medicines and vaccines essential for patient safety and outcomes, says ABPI
News |
ABPI response to NHS 10-Year Health Plan
Blog |
Disclosure UK 2024: new record for transparency, with nine in ten healthcare professionals named in database
Best practice guidance: Supporting patient organisations to report industry funding
Transparency is essential when pharmaceutical companies work with patient organisations. This updated guidance is aimed at supporting that transparency.
Guidance for conferences and events in the UK: ABPI Code of Practice requirements
This clarifies the ABPI Code requirements for conferences and events, helps all relevant stakeholders operate in a Code-compliant, professional and ethical manner.
2024 ABPI Code of Practice – new resources
The PMCPA has published new webinars and e-learning to aid understanding of the 2024 ABPI Code of Practice.
Lives Lived Well
From patients and their loved ones to those working within the pharmaceutical industry in the UK, we share a common goal: Lives Lived Well.
Events
Online Workshop on SMC: How to prepare and submit to SMC | 08-09 September 2025
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
Save the date - ABPI Industry Summit 2025
ABPI Annual Conference 2026
ABPI’s flagship annual conference will be taking place in Central London on 23 April 2026.
Publication of A Common Understanding 2025
The Common Understanding 2025 publication demonstrates the value of productive relationships between the pharmaceutical industry and other partners in Scotland.
Key facts and figures for the pharmaceutical industry in the UK
£46.7bn
Turnover [6]
£9bn
investment in UK R&D (more than UKRI’s entire annual budget) [3]
£17.6bn
direct Gross Value Added (GVA) [1]